One of the first patent infringement suits over CRISPR gene editing technology is set for a preliminary injunction showdown Thursday in San Jose federal court.

U.S. District Judge Edward Davila will confront a few oddities as Agilent Technologies Inc. tries to block sales of Synthego Corp.’s gene-editing tools. Redwood City-based Synthego Corp. originally sued Agilent for a declaration of noninfringement but has since shifted its focus to patent validity—specifically, its Patent Trial and Appeal Board (PTAB) validity challenge to Agilent Technologies’ 10,337,001 and 10,900,034 patents.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]